Study Title: A randomized, placebo-controlled, double-blind study on the effects of (−)-epicatechin on the triglyceride/HDLc ratio and cardiometabolic profile of subjects with hypertriglyceridemia: Unique in vitro effects
Citation: Gutiérrez-Salmeán et al., 2016 · International Journal of Cardiology
What the Study Found: In hypertriglyceridemic subjects, 100 mg/day of (−)-epicatechin for 4 weeks significantly improved the triglyceride/HDLc ratio and other cardiometabolic markers. In parallel in vitro experiments, (−)-epicatechin reduced fructose-induced triglyceride accumulation and improved mitochondrial function in liver cells. The effects were superior to those of its stereoisomer (+)-catechin.
What this means in real life: Mitochondria in the liver and muscle are central to balancing fat and sugar metabolism; when they’re stressed, triglycerides rise and HDL falls. This human trial shows that (−)-epicatechin can shift cardiometabolic markers in a favorable direction while directly protecting mitochondrial function in liver cells. Mitochondrial support like this offers a practical way to improve everyday metabolic health and energy efficiency.
Contenu associé
- Curious how mitochondrial health influences fat metabolism and body composition? → Mitochondrial Dysfunction and Obesity: What’s the Connection?
- Want to understand how cellular energy shapes metabolic resilience? → Women’s Metabolic Health: Hormones, Energy, and Resilience
- Looking for ways to support mitochondrial function daily? → How to Repair and Maintain Mitochondrial Health Naturally